Loading the section…
The price of Xenon Pharmaceuticals Inc. (XENE) on October 9, 2026 is 36.44 USD, +0.77% on the day. Over 52 weeks the stock traded between 35.06 USD and 72.66 USD; the price now sits 4% of the way up that range. Over the past year the price changed by -7.16%. Market capitalization is 3.52 billion USD, rank 48 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 2 November 2026 · Earnings calendar
Change over the period shown (line colour): −8.88 %
Xenon Pharmaceuticals Inc. trades on Nasdaq under the ticker XENE. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks XENE has traded between 35.06 $ and 72.66 $. As of 9 October 2026 the price stood 3.67 % of the way from the 52-week low to the high.
Over one year XENE shares fell 7.16 %; over six months they fell 37.60 %. Volatility over 90 days is 71.91 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to book is 2.6, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 36.05 | 36.70 | 35.98 | 36.44 | 1M |
| 8 October 2026 | 36.13 | 36.41 | 35.06 | 36.16 | 2M |
| 7 October 2026 | 36.19 | 36.56 | 35.78 | 36.41 | 2M |
| 6 October 2026 | 37.78 | 37.79 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Xenon Pharmaceuticals Inc. (XENE) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 0 $, net income was -383.2m $. Incorporated in CA.
This summary is compiled automatically from SEC filings and exchange data.
Address:200 - 3650 GILMORE WAY, BURNABY
Xenon Pharmaceuticals Inc. reported revenue of 0 $ and a net loss of 383M $ over the last four quarters. Revenue changed by −100.00 % year over year. Earnings per share are −4.70 $. Market capitalisation is 3.5B $.
XENE has a return on equity of −28.64 %, above the sector median of −41.68 %. Return on assets is −27.63 %, above the sector median of −32.11 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 35.75 |
| 36.57 |
| 3M |
| 5 October 2026 | 38.02 | 38.23 | 37.00 | 37.57 | 2M |
| 2 October 2026 | 39.10 | 39.10 | 37.26 | 38.02 | 2M |
| 1 October 2026 | 38.31 | 39.92 | 38.08 | 38.93 | 4M |
| 30 September 2026 | 37.38 | 37.53 | 36.71 | 37.19 | 2M |
| 29 September 2026 | 36.30 | 37.43 | 36.20 | 37.25 | 3M |
| 28 September 2026 | 36.85 | 36.85 | 36.10 | 36.72 | 3M |
| 25 September 2026 | 38.10 | 38.26 | 36.48 | 36.94 | 2M |
| 24 September 2026 | 36.50 | 38.34 | 36.07 | 38.06 | 3M |
| 23 September 2026 | 39.51 | 39.51 | 36.07 | 36.56 | 3M |
| 22 September 2026 | 39.76 | 39.76 | 37.97 | 39.09 | 2M |
| 21 September 2026 | 40.00 | 40.26 | 38.61 | 38.99 | 4M |
| 18 September 2026 | 44.02 | 44.85 | 39.08 | 39.75 | 18M |
| 17 September 2026 | 57.60 | 58.15 | 56.87 | 57.35 | 2M |
| 16 September 2026 | 56.67 | 57.88 | 56.40 | 56.76 | 723,600 |
| 15 September 2026 | 58.13 | 58.13 | 56.17 | 56.28 | 587,000 |
| 14 September 2026 | 59.36 | 59.60 | 58.00 | 58.19 | 408,500 |